Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
23 Jul 2025
// GLOBENEWSWIRE
31 May 2025
// BUSINESSWIRE
23 May 2025
// GLOBENEWSWIRE
22 May 2025
// FIERCE PHARMA
27 Jan 2025
// BUSINESSWIRE
11 Nov 2024
// GLOBENEWSWIRE
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]US Exclusivities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Health Canada Patents
Patent Expiration Date : 1930-09-27
Date Granted : 2017-10-03
Brand Name : ITOVEBI
Patent Number : 2772691
Filing Date : 2010-09-27
Strength per Unit : 3 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1930-09-27
Date Granted : 2017-10-03
Patent Expiration Date : 1936-07-01
Date Granted : 2023-10-03
Brand Name : ITOVEBI
Patent Number : 2982708
Filing Date : 2016-07-01
Strength per Unit : 3 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1936-07-01
Date Granted : 2023-10-03
Patent Expiration Date : 1930-09-27
Date Granted : 2017-10-03
Brand Name : ITOVEBI
Patent Number : 2772691
Filing Date : 2010-09-27
Strength per Unit : 9 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1930-09-27
Date Granted : 2017-10-03
Patent Expiration Date : 1936-07-01
Date Granted : 2023-10-03
Brand Name : ITOVEBI
Patent Number : 2982708
Filing Date : 2016-07-01
Strength per Unit : 9 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1936-07-01
Date Granted : 2023-10-03
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
76
PharmaCompass offers a list of Inavolisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Inavolisib manufacturer or Inavolisib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Inavolisib manufacturer or Inavolisib supplier.
A INAVOLISIB [WHO-DD] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of INAVOLISIB [WHO-DD], including repackagers and relabelers. The FDA regulates INAVOLISIB [WHO-DD] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. INAVOLISIB [WHO-DD] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A INAVOLISIB [WHO-DD] supplier is an individual or a company that provides INAVOLISIB [WHO-DD] active pharmaceutical ingredient (API) or INAVOLISIB [WHO-DD] finished formulations upon request. The INAVOLISIB [WHO-DD] suppliers may include INAVOLISIB [WHO-DD] API manufacturers, exporters, distributors and traders.
INAVOLISIB [WHO-DD] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of INAVOLISIB [WHO-DD] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right INAVOLISIB [WHO-DD] GMP manufacturer or INAVOLISIB [WHO-DD] GMP API supplier for your needs.
A INAVOLISIB [WHO-DD] CoA (Certificate of Analysis) is a formal document that attests to INAVOLISIB [WHO-DD]'s compliance with INAVOLISIB [WHO-DD] specifications and serves as a tool for batch-level quality control.
INAVOLISIB [WHO-DD] CoA mostly includes findings from lab analyses of a specific batch. For each INAVOLISIB [WHO-DD] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
INAVOLISIB [WHO-DD] may be tested according to a variety of international standards, such as European Pharmacopoeia (INAVOLISIB [WHO-DD] EP), INAVOLISIB [WHO-DD] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (INAVOLISIB [WHO-DD] USP).
Share
